Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study.

Wang CJ, Lin YN, Huang SW, Chang CH

The Journal of urology13 Nov 2010Cited by 39 (Europe PMC)

PMID21074790DOI10.1016/j.juro.2010.08.095PepBankPUB-21074790

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In elderly patients with benign prostatic hyperplasia, desmopressin significantly decreased nocturnal urine output (p < 0.01).
In plain wordsIn elderly patients with prostate enlargement, desmopressin reduced nighttime urine output.
Peptide
Desmopressin
Outcome
DecreaseNocturnal urine output
Study
n = 115
Outcome group
Urine Production · Kidney and urinary
Studied dose
0.1 mg at bedtime · oral · 12 monthsAs given in this study (human).
Source sentences
Summary
Desmopressin significantly decreased nocturnal urine output and the number of nocturia episodes, and prolonged the first sleep period (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study.
Summary · context
All patients received placebo or 0.1 mg desmopressin orally at bedtime.
Summary · context
A total of 115 patients were enrolled in the study and randomized as 58 in the placebo group and 57 in the desmopressin group.
Report a problemFND-2107479001
02HumanNon-randomized trialEfficacy outcome
In elderly patients with benign prostatic hyperplasia, desmopressin significantly decreased nocturia episodes (p < 0.01).
In plain wordsIn elderly patients with prostate enlargement, desmopressin reduced nighttime urination episodes.
Peptide
Desmopressin
Outcome
DecreaseNocturia episodes
Study
n = 115
Outcome group
Nocturia · Kidney and urinary
Studied dose
0.1 mg at bedtime · oral · 12 monthsAs given in this study (human).
Source sentences
Summary
Desmopressin significantly decreased nocturnal urine output and the number of nocturia episodes, and prolonged the first sleep period (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study.
Summary · context
All patients received placebo or 0.1 mg desmopressin orally at bedtime.
Summary · context
A total of 115 patients were enrolled in the study and randomized as 58 in the placebo group and 57 in the desmopressin group.
Report a problemFND-2107479002
03HumanNon-randomized trialEfficacy outcome
In elderly patients with benign prostatic hyperplasia, desmopressin significantly prolonged the first sleep period (p < 0.01).
In plain wordsIn elderly patients with prostate enlargement, desmopressin increased the first sleep period.
Peptide
Desmopressin
Outcome
IncreaseFirst sleep period
Study
n = 115
Outcome group
Sleep · Sleep
Studied dose
0.1 mg at bedtime · oral · 12 monthsAs given in this study (human).
Source sentences
Summary
Desmopressin significantly decreased nocturnal urine output and the number of nocturia episodes, and prolonged the first sleep period (p < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study.
Summary · context
All patients received placebo or 0.1 mg desmopressin orally at bedtime.
Summary · context
A total of 115 patients were enrolled in the study and randomized as 58 in the placebo group and 57 in the desmopressin group.
Report a problemFND-2107479003
04HumanNon-randomized trialSafety outcome
In elderly patients with benign prostatic hyperplasia, desmopressin gradually decreased serum sodium compared with pretreatment.
In plain wordsIn elderly patients with prostate enlargement, desmopressin gradually lowered blood sodium compared with before treatment.
Peptide
Desmopressin
Outcome
DecreaseSerum sodium
Study
n = 57
Comparator
Before treatment
Outcome group
Adverse events · Endocrine and hormones
Studied dose
0.1 mg at bedtime · oral · 12 monthsAs given in this study (human).
Source sentences
Summary
Compared to before treatment desmopressin gradually decreased serum sodium and induced statistically but not clinically significant hyponatremia after 12 months of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study.
Summary · context
All patients received placebo or 0.1 mg desmopressin orally at bedtime.
Summary · context
A total of 115 patients were enrolled in the study and randomized as 58 in the placebo group and 57 in the desmopressin group.
Report a problemFND-2107479004
05HumanNon-randomized trialSafety outcome
In elderly patients with benign prostatic hyperplasia, desmopressin induced statistically but not clinically significant hyponatremia after 12 months.
In plain wordsIn elderly patients with prostate enlargement, desmopressin caused statistically significant low sodium after 12 months, without clinical significance.
Peptide
Desmopressin
Outcome
IncreaseHyponatremia
Study
n = 57
Comparator
Before treatment
Outcome group
Adverse events · Endocrine and hormones
Studied dose
0.1 mg at bedtime · oral · 12 monthsAs given in this study (human).
Source sentences
Summary
Compared to before treatment desmopressin gradually decreased serum sodium and induced statistically but not clinically significant hyponatremia after 12 months of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study.
Summary · context
All patients received placebo or 0.1 mg desmopressin orally at bedtime.
Summary · context
A total of 115 patients were enrolled in the study and randomized as 58 in the placebo group and 57 in the desmopressin group.
Report a problemFND-2107479005
06HumanNon-randomized trialSafety outcome
In the desmopressin trial in elderly patients with benign prostatic hyperplasia, no serious systemic complications occurred during medication.
In plain wordsIn the desmopressin trial in elderly patients with prostate enlargement, no serious systemic complications occurred during medication.
Peptide
Desmopressin
Outcome
Not applicableSerious systemic complications
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.1 mg at bedtime · oral · 12 monthsAs given in this study (human).
Source sentences
Summary
No serious systemic complications were found during medication.
3 context sentences(design, population, supporting numbers)
Summary · context
Eligible patients with benign prostatic hyperplasia older than 65 years with nocturia, nocturnal polyuria and International Prostate Symptom Score 14 or greater were included in the study.
Summary · context
All patients received placebo or 0.1 mg desmopressin orally at bedtime.
Summary · context
A total of 115 patients were enrolled in the study and randomized as 58 in the placebo group and 57 in the desmopressin group.
Report a problemFND-2107479006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.